Yeast Colonization and Drug Susceptibility Pattern in the Pediatric Patients with Neutropenia

Overview

Journal Jundishapur J Microbiol

Publisher Brieflands

Specialty Microbiology

Date 2014 Dec 9

PMID 25485060

Citations 23

Authors

Pedram Haddadi

Soheila Zareifar

Parisa Badiee

Abdolvahab Alborzi

Maral Mokhtari

Kamiar Zomorodian

Keyvan Pakshir

Hadis Jafarian

Affiliations

Soon will be listed here.

Abstract

Background: Pediatric patients with neutropenia are vulnerable to invasive Candida infections. Candida is the primary cause of fungal infections, particularly in immunosuppressed patients. Candida albicans has been the most common etiologic agent of these infections, affecting 48% of patients.

Objectives: The aim of this study was to identify Candida spp. isolated from children with neutropenia and determine the antifungal susceptibility pattern of the isolated yeasts.

Patients And Methods: In this study 188 children with neutropenia were recruited, fungal surveillance cultures were carried out on nose, oropharynx, stool, and urine samples. Identification of Candida strains was performed using germ tube and chlamydospore production tests on an API 20 C AUX system. Susceptibility testing on seven antifungal agents was performed using the agar-based E-test method.

Results: A total of 229 yeasts were isolated. Among those, C. albicans was the most common species followed by C. krusei, C. parapsilosis, C. glabrata, C. tropicalis, C. famata, C. dubliniensis, C. kefyr, and other Candida species. C. glabrata was the most resistant isolated yeasts, which was 70% resistant to fluconazole and 50% to itraconazole, 7.5% to amphotericin B and 14% to ketoconazole. All the tested species were mostly sensitive to caspofungin.

Conclusions: Knowledge about the susceptibility patterns of colonized Candida spp. can be helpful for clinicians to manage pediatric patients with neutropenia. In this study, caspofungin was the most effective antifungal agent against the colonized Candida spp. followed by conventional amphotericin B.

Citing Articles

Predictors of Candidemia during Febrile Episode in Lymphoreticular Malignancy Affecting Paediatric Population.

Gautam S, Das S, Singh P, Rai G, Jain C, Saha R Diagnostics (Basel). 2023; 13(9).

PMID: 37175029 PMC: 10177753. DOI: 10.3390/diagnostics13091638.

Antifungal Resistance of Clinical Isolates in Iran: A Systematic Review and Meta-Analysis.

Kermani F, Taghizadeh-Armaki M, Hosseini S, Amirrajab N, Javidnia J, Fami Zaghrami M Iran J Public Health. 2023; 52(2):290-305.

PMID: 37089147 PMC: 10113589. DOI: 10.18502/ijph.v52i2.11874.

Oral colonization and anti-fungal susceptibility pattern in patients with hematological malignancy.

Talebshoushtari Zadeh M, Lotfali E, Fattahi M, Abolgasemi S Curr Med Mycol. 2023; 8(3):18-22.

PMID: 37051553 PMC: 10084485. DOI: 10.18502/cmm.8.3.11210.

Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates.

Yazdanpanah S, Ahmadi M, Zare Z, Nikoupour H, Arabsheybani S, Jabrodini A Mycopathologia. 2022; 188(1-2):9-20.

PMID: 36495418 PMC: 9739341. DOI: 10.1007/s11046-022-00694-x.

Phenotype, genotype, and mating type determination in oral Candida albicans isolates from pediatric patients with neutropenia.

Jafarian H, Gharaghani M, Asnafi A, Hardani A, Zarei-Mahmoudabadi A J Clin Lab Anal. 2022; 36(9):e24664.

PMID: 36082467 PMC: 9459309. DOI: 10.1002/jcla.24664.

References

Dannaoui E, Lortholary O, Dromer F . In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother. 2004; 48(3):970-8. PMC: 353155. DOI: 10.1128/AAC.48.3.970-978.2004. View

Badiee P, Kordbacheh P, Alborzi A, Zakernia M, Haddadi P . Early detection of systemic candidiasis in the whole blood of patients with hematologic malignancies. Jpn J Infect Dis. 2009; 62(1):1-5. View

Maa S, Lee H, Huang Y, Hsieh Wu J, Tsou T, MacDonald K . Incidence density and relative risk of nosocomial infection in Taiwan's Only Children's Hospital, 1999-2003. Infect Control Hosp Epidemiol. 2008; 29(8):767-70. DOI: 10.1086/589724. View

Fidel Jr P, Vazquez J, Sobel J . Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev. 1999; 12(1):80-96. PMC: 88907. DOI: 10.1128/CMR.12.1.80. View

Farmaki E, Evdoridou J, Pouliou T, Bibashi E, Panagopoulou P, Filioti J . Fungal colonization in the neonatal intensive care unit: risk factors, drug susceptibility, and association with invasive fungal infections. Am J Perinatol. 2007; 24(2):127-35. DOI: 10.1055/s-2007-970078. View

Pammi M, Eddama O, Weisman L . Patient isolation measures for infants with candida colonization or infection for preventing or reducing transmission of candida in neonatal units. Cochrane Database Syst Rev. 2011; (11):CD006068. PMC: 7389412. DOI: 10.1002/14651858.CD006068.pub3. View

White T, Holleman S, Dy F, Mirels L, Stevens D . Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2002; 46(6):1704-13. PMC: 127245. DOI: 10.1128/AAC.46.6.1704-1713.2002. View

Posteraro B, Sanguinetti M, Fiori B, La Sorda M, Spanu T, Sanglard D . Caspofungin activity against clinical isolates of azole cross-resistant Candida glabrata overexpressing efflux pump genes. J Antimicrob Chemother. 2006; 58(2):458-61. DOI: 10.1093/jac/dkl237. View

Badiee P, Alborzi A . Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study. Iran J Microbiol. 2012; 3(4):183-8. PMC: 3330181. View

10.

Masia Canuto M, Gutierrez Rodero F . Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis. 2002; 2(9):550-63. DOI: 10.1016/s1473-3099(02)00371-7. View

11.

Badiee P, Alborzi A, Joukar M . Molecular assay to detect nosocomial fungal infections in intensive care units. Eur J Intern Med. 2011; 22(6):611-5. DOI: 10.1016/j.ejim.2011.08.025. View

12.

Garcia San Miguel L, Cobo J, Otheo E, Sanchez-Sousa A, Abraira V, Moreno S . Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: emergence of Candida parapsilosis. Infect Control Hosp Epidemiol. 2005; 26(6):548-52. DOI: 10.1086/502582. View

13.

Filioti J, Spiroglou K, Roilides E . Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. Intensive Care Med. 2007; 33(7):1272-1283. DOI: 10.1007/s00134-007-0672-5. View

14.

Badiee P, Alborzi A, Shakiba E, Farshad S, Japoni A . Susceptibility of Candida species isolated from immunocompromised patients to antifungal agents. East Mediterr Health J. 2011; 17(5):425-30. View

15.

Zaoutis T, Foraker E, McGowan K, Mortensen J, Campos J, Walsh T . Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals. Diagn Microbiol Infect Dis. 2005; 52(4):295-8. DOI: 10.1016/j.diagmicrobio.2005.03.002. View

16.

Pfaller M, Messer S, Boyken L, Tendolkar S, Hollis R, Diekema D . Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol. 2004; 42(7):3142-6. PMC: 446248. DOI: 10.1128/JCM.42.7.3142-3146.2004. View

17.

Pfaller M, Boyken L, Hollis R, Messer S, Tendolkar S, Diekema D . In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol. 2006; 44(3):760-3. PMC: 1393154. DOI: 10.1128/JCM.44.3.760-763.2006. View

18.

Saiman L, Ludington E, Dawson J, Patterson J, Wiblin R, Blumberg H . Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J. 2001; 20(12):1119-24. DOI: 10.1097/00006454-200112000-00005. View

19.

Marodi L, Johnston Jr R . Invasive Candida species disease in infants and children: occurrence, risk factors, management, and innate host defense mechanisms. Curr Opin Pediatr. 2007; 19(6):693-7. DOI: 10.1097/MOP.0b013e3282f1dde9. View

20.

Carrillo-Munoz A, Giusiano G, Ezkurra P, Quindos G . Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006; 19(2):130-9. View